The article focuses on the results of the randomized Phase III study of bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment for indolent and mantle cell lymphomas (MCL). It says that the progression-free survival (PFS) in patients with MCL was significantly prolonged with B-R compared with CHOP-R. It mentions that B-R has shown a PFS benefit and tolerability improvement than CHOP-R.